FogPharma
Donovan Chin has extensive experience in the field of computational drug discovery and structural biology. Donovan started their career as a Consultant at Accelrys in 1991 and later worked as a Computational Chemist at Moldyn. Donovan then held roles as a Computational Informatics at TransForm Pharmaceuticals, a Senior Scientist at Biogen Idec, a Research Investigator III at Novartis, and a Senior Investigator I, Director of Computational Drug Discovery and Structural Biology at Novartis. Donovan's most recent positions include Associate Vice President and Vice President of Computational Drug Discovery at FogPharma.
Donovan Chin completed a Bachelor of Science in Chemistry from the University of Florida in 1987. Donovan then pursued a PhD in Computational Polymer Science at the University of Massachusetts Lowell from 1987 to 1992. Finally, they obtained a PostDoc in Computational Chemistry from Harvard University from 1992 to 1996.
This person is not in any teams
FogPharma
1 followers
FogPharma is dedicated to the creation of a new class of medicines that target human disease drivers currently considered “undruggable.” The company’s cell-penetrating miniproteins (CPMPs) combine the targeting power of protein therapeutics with the cell-penetrating ability of small molecules. This unique combination of targeting features enables CPMP’s to access and engage proteins that have long been known to play a major role in causing serious human diseases, but have been frustratingly beyond the reach of therapeutic intervention.